Drug addiction has been correctly assigned to the field of mental illness, due to the nature of its symptoms, clinical picture, and its pathophysiological pathways within the central nervous system. Some similarities have emerged between addictive symptoms and psychiatric diseases such as hypomania and impulse control disorders, including borderline and antisocial personality disorders (for all of which we envisage a common genetic diathesis). Nevertheless, once established, addiction exhibits an autonomous process, and the coexistence with other mental disorders represents a condition of dual diagnosis. The co-existence with other mental disorders shares neurobiological ground on which certain psychopathologic dispositions impart an enhanced risk of becoming addicted. In particular, we suggest that the bipolar spectrum-and its hyperthymic and cyclothymic temperamental substrates-is at special risk for substance use, possibly stepping toward addiction through enduring exposure to intrinsically dependence-producing substances. In our experience, the contribution of bipolarity to the addictive process is often missed because subclinical expressions of bipolarity along temperamental extremes are insufficiently appreciated by both psychiatrists and addictionologists. Finally, the use of agonist treatment in dual diagnosis heroin addicts has allowed us to gather valuable knowledge about their intrinsic, and historically and clinically documented, mood-regulating effects. We submit that the present conceptualization of the link between addictive and bipolar disorders has heuristic clinical and scientific merits.
ADDICTION AS A MENTAL DISEASE
To date, in spite of the definitions provided by the WHO and the APA of drug addiction as a mental disorder, 1 many healthcare operators are still reluctant to adopt the disease model for the management of addiction-related problems. Thus, the specificity of a medical approach to the treatment of addiction is often questioned and criticized as a medicalization of addiction. [2] [3] [4] [5] [6] [7] Likewise, complexity in the appearance of addictionrelated phenomena is thought of as springing from a social structure of addiction such that the latter often goes beyond the sphere of the affected individual to involve the context of family and socially connected figures. By contrast, in approaching addicted individuals, clinical practitioners have a direct experience of how the basic dynamics of addictive behaviors unfolds between the substance and the affected person, so that the shared ground of addictive phenomenology is located within the sphere of individual distress and dysfunction. Its core symptoms, craving and relapsing-behavior, are linked along linear dynamics, leading from elicited desire to appetitive action through behavioral planning of variable complexity, while remaining essentially focused on a primary instinctual drive and appetitive behavioral patterns. 8 From a medical viewpoint, addiction is a conduct disorder developed through prolonged exposure to some intrinsically addictive substances. As a disease, addiction essentially impairs the individual's capability to achieve any subjectively pleasant equilibrium, while his or her pleasure-seeking be-havior grows to a counterproductive, dysfunctional level. Far from being just a deviant lifestyle pattern, or a rewarding "personal choice" for deviance, addiction never provides a balance, whether it be a deviant or a more extreme antisocial type. It does, in fact, display as a metabolic brain disease that achieves expression through a hypertrophic kind of behavioral disturbance, though all this may too often be obscured by the complexity of the social issues it usually raises. 9, 10 
TOWARD A PSYCHOPATHOLOGY OF ADDICTIVE BEHAVIORS AS DERIVED FROM GENERAL PSYCHIATRY
Addictive psychopathology appears to consist of elements, such as craving and loss of control over instinctual drives, that are quite common in general psychiatry. Craving, for instance, displays as a powerful urge to attain an objective, such as a drug, or some non-chemical form of stimulation. 11 The chronic course and self-perpetuating loop of addiction, through which affected individuals find their way into relapse, is frequently observed for other mental disorders as well. The core features of the addictive symptoms are the keys that justify the inclusion in the field of psychiatry, without making it part of intoxication-related phenomenology or psychologic discomfort due to social deterioration. A common misconception about the link between psychiatry and the field of addictions relies on the self-medication hypothesis. 12, 13 In reality, addicts for whom selfmedicating pathophysiology is regarded as very likely fall into the category of substanceabusing mentally ill patients, and their addictive behavior is considered as a way to overcome the discomfort caused by the mental disorder. In most cases, however, these "selfmedicating" addicts continue to use substances even when there is no further psychopathology, or when discomfort associated with mental disorder is worsened. This is the most common evolution even when self-medicating attitude might have been clearly evident for the same substance and the same individual at an earlier stage. 14 During an addictive stage, substance use should be countered by an anti-craving and behavior-normalizing psychotropic intervention, regardless of concurrent psychopathology. Despite this, some similarities can be noted between general psychopathology and addictive symptoms. Traditional descriptions of addictive syndromes focus on the patient's loss of resources and ties with society, as well as the ability to cope, thereby suggesting some resemblance to affective conditions. Adopting a psychopathology-based perspective, craving-related urges and substance-bound behaviors closely resemble the hypomanic excitement of bipolar patients; the substance itself is a dominant theme and aim, and it is pursued with an overwhelming appetitive drive. Thus, beyond the similarities between their clinical picture, mania and addiction share a common ground of excitement and impulsive overactivity. The usual perception of addiction as a compulsive habit, grounded on an irresistible urge that supports relapse into drug use, may be misleading. Individuals who self-administer drugs learn to do so to elicit pleasure, following a subjectively positive goal. This is reminiscent of an ego-syntonic impulsive behavior. On the other hand, compulsiveness indicates an incapacity to refrain from certain actions that are meant to buffer obsessively recurrent thoughts, with no objective to attain, but enacting a harm-avoidant mode. To sum up, rather than compels, craving is an urge that drives the affected individual to selfstimulation.
ON THE CONCEPT OF DUAL DIAGNOSIS
When addiction is coupled with another mental disorder, we resort to a dual diagnosis. It is implied that the coexisting entities are different entities rather than just related psychopathological syndromes. This makes dual diagnosis a special subtype of co-morbidity as it is customarily used in the current medical and psychiatric literature. While concomitant disorders may stem from a common substrate, co-morbidity imply that they spring from relatively distinct processes; nonetheless, addiction and other mental disorders share a common metabolic ground, with the brain as the targeted organ, so that mutual interaction between them is not just an additional clinical issue, but the crucial foundation on which to build a combined pathophysiological model 15 and related treatment approaches. It follows that the challenge of dual diagnosis calls for an ability to count on double, combined medical skills, to adequately respond to the specificity of the problem.
Different psychiatric conditions may have different impacts on substance use; they may involve different interactions with substances, and have a different relationship with self-administration practices. Some of them, like affective disorders, share the reverberating, self-maintaining, and self-enhancing mechanism of addictive diseases. As a result of the two substrates catalyzing each other, both clinical pictures are likely to be exacerbated. In particular, affective disorders amplify the behavioral reinforcement produced by substances, and thereby enhance the likelihood of their use. Moreover, the repeated exposure to a psychoactive substance and the acquisition of the euphoric experience as the new level of satisfaction result in a further impairment of mood stability.
THE BIPOLAR SPECTRUM
Bipolar disorders are a group of chronically recurring diseases characterized by enduring prolonged mood instability and leaning toward states of depression and excitement. Swinging between depression and elation is typical, and episodes can also occur in which opposite symptoms of excitement and inhibition are combined (mixed states). Mood swings vary in severity, duration, and sequence. Excitement following worthwhile life events and, at a much later stage, substance-induced excitement, have been re-garded as signs of bipolar disposition, thus superseding the dichotomy between spontaneous and induced euphoria. 16 Despite their apparent "stable instability," the mood states of bipolar subjects are changeable by definition. Major mood swinging may remain latent through symptom free intervals, although recent research has noted the prevalence and clinical relevance of enduring sub-threshold pre-morbid, interepisodic, and residual symptoms. Switches from one state to another may be gradual or extremely rapid, and may mostly follow external stimulation or be spontaneous and selftriggering.
The different forms of bipolar disorder are classified according to the presence of hypomanic (bipolar II) or manic-mixed episodes (bipolar I), and are reasonably grouped in a common broad spectrum of severity from temperament to psychosis, suggesting that some shared biologic disposition underlies a range of phenotypes. 17 The best known and most longstanding diagnoses include: bipolar I disorder, featuring major manic, depressive, or mixed episodes, with possible psychotic symptoms such as delusions and hallucinations; bipolar II, alternating between hypomania and major depression; and cyclothymic disorder, alternating between subclinical episodes of either mode. 18 Physiological and temperamental conditions that fall below the threshold for mental disorder are, nonetheless, linked to clinical mood disorders as early expressions of a core disposition of mood instability. Moreover, some clinical pictures usually known as personality disorders have recently been re-proposed as a combination of bipolar disorders and temperamental excesses. This is particularly true for borderline personality disorder and related "psychopathic" conditions. 19 The concept of bipolar spectrum also comprises some early-onset anxiety syndromes and conduct disorders, which seem to predict future major mood swinging in temperamentally predisposed individuals. In this view, early childhood anxiety disorders combined with Maremmani et al symptoms of behavioral excitement or affective temperaments may account for mania or hypomania to supervene. Meanwhile, some genetic and clinical clustering seems to stand within the field of bipolar syndromes; thus, bipolar I disorder appears to be a major psychotic disorder, while a series of neurotic conditions sharing chronic dysphoria, impulsiveness, and risk behaviors seems to cluster around the bipolar II phenotype. [20] [21] [22] [23] 
ADDICTION AND THE BIPOLAR SPECTRUM
Alcohol, cocaine, and cannabis are commonly abused by bipolar patients, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] especially during manic states, 24, 27, 30, 31, [35] [36] [37] with greater probability than among unipolar depressed subjects. 31, 32 On the other hand, mood disorders are the most frequent form of psychiatric co-morbidity for addiction. [38] [39] [40] [41] [42] [43] [44] [45] Depressive episodes are quite common in various phases of a history of addiction, both before and after treatment, whereas manic syndromes seem to be quite rare. [46] [47] [48] [49] Considering the well-known anti-dysphoric properties of opiates, it has been hypothesized and speculated that initially heroin is taken to fight dysphoria, and is needed later because of acquired tolerance to its anti-dysphoric action and increased susceptibility to dysphoria in its absence. Abused opiates may thus bind abusers to a self-medicating behavior, viciously weakening inner resources. 13 By contrast, the PISA-SIA Group expresses a different viewpoint, on the basis of clinical experience: most addicts recall euphoria as the original reason for drug taking, and seem to chase pleasure by heroin even when they have become highly tolerant to it. As a result, they show no preference, and hardly any appetite, for cross-acting anti-withdrawal substances such as methadone, which fail to produce euphoria in tolerant brains. Therefore, the self-medication theory does not seem to be the only key to an understanding of the dynamics of addiction, though it may give a crucial insight into how a drug using habit became stable in a subgroup of would-be addicts.
In our evaluation, axis I bipolar disorders were commonest among dual diagnosis heroin addicts admitted into a methadone maintenance treatment program, 34, 50 whereas Unipolar Depressive Disorders were far less frequent, to the same extent as Psychotic Disorders. Bipolar disorder is also frequent in a naltrexone-maintained population, though mostly in its type II form. 51 As for other substances, we evaluated psychotic patients with and without a history of cannabis use; bipolar psychotics, especially schizophrenic psychotics, were those most likely to have a current and past status of cannabis use. Moreover, bipolar patients displayed a stronger probability than nonbipolars of continuing in their drug use habit, despite all consequences. The spontaneous interruption of substance abuse turned out to be symptomatic of non-affective psychosis. 52 Thus, bipolar disorders seem to occur regardless of a patient's degree of addiction severity, whether among low-severity abusers, for whom naltrexone treatment is suitable, or among average-to-high severity ones, who should receive methadone treatment. [53] [54] [55] Consistent with this view, the evidence of proneness to substance abuse is distributed over the entire bipolar spectrum. In fact, a high probability of substance abuse is not only found among subjects with axis I bipolar disorders. A family history of bipolar II disorder is linked to alcohol abuse among socially phobic patients, 56 and stands as a biologic predisposition that explains the greater impulsiveness and risk-taking among HIV-positive patients with respect to their HIV-negative peers. 57 Temperament profiles may also contribute to an understanding of the role of mood in drug-related phenomena. Hyperthymic and irritable temperaments were found to be at risk for substance use in a large sample of 1010 mentally healthy individuals evaluated along Akiskal and Mallya's TEMPS-I scale 19 substance-use habits. The higher the score is on the hyperthymic scale, the greater the risk of alcohol use (unpublished data). Moreover, cyclothymic temperament was related to alcohol abuse in a population of patients with atypical depressive pictures. 59 As for heroin addicts, we assessed affective temperaments by a self-rated version of Akiskal and Mallya's scale (TEMPS-A) 19 in a sample of methadone-maintained addicts and a control group of non-abusers from the same environment; cyclothymic temperament was the most represented among heroin addicts, and the only one able to distinguish addicts from controls. 51, 60 Moreover, the cyclothymic temperamental link has been proved to be independent from the dual diagnosis status of heroin addicts, thereby providing an explanatory model that points to underlying physiology rather than full-blown pathology. As concerns the entire affective temperamental profile, heroin addicts showed a prototype of a major element of mood instability and a less prominent one of depressive traits. Finally, the absence of any affective temperament combined with the absence of any family history of affective disorder was the least likely condition among heroin addicts. 51 Borderline patients are simultaneously characterized by impulsive behavior and substance abuse, the latter possibly triggered by dysphoric mood swings or reactions. The borderline phenotype has recently been described as a variant of bipolar disorder, due to its close resemblance to cyclothymia with comorbid features, including anxious and addictive disorders. 16, 18, 19 Even so, it has been shown that, in these patients who experience intense, rapid onset and offset of mood states, substance use is mostly triggered by specific substance-related cues rather than subjectively unpleasant feelings, 61 such as those that underlie self-injuring behaviors.
The actual role of bipolar disposition in substance-related issues is best defined when taking into account the observation that cyclothymic and hyperthymic temperaments also discriminate HIV-positive from HIV-negative patients. 57 This prompts the hypothesis that temperaments have a direct influence on the long term course and prognosis of the illness, since they represent a constitutional predisposition to risk-taking, thereby amplifying the intrinsic harmful or addictive properties of certain infective as well as psychotropic agents. On the other hand, subjects with a bipolar-prone biologic structure may differ from their peers as to the quality and intensity of substance-elicited euphoria. A predisposition to euphoria has been demonstrated as peculiar to bipolar patients in a group of depressed patients. 62
THE THERAPEUTIC FRONTIER: MOOD-REGULATING PROPERTIES OF SLOW-ACTING OPIATES
The use of opioid drugs in the treatment of mental disorders remains untried so far, despite evidence of their antidysphoric, anxiolytic, and anti-aggressive effects. 63 Regrettably, the fear of favoring an epidemic of opiate addiction, regardless of the opiate to be used, has overwhelmed scientific interest in the primary psychotropic properties of opiates and clinicians' demand for drugs able to demonstrate an anti-aggressive and antidysphoric efficacy. Opiates have been used for opiate-tolerant individuals, in the treatment of pain and opiate abuse, with only a small body of evidence concerning the treatment of depression, 64-66 not leading to actual clinical application. As a result, most of our knowledge about the psychotropic properties of opiates has been drawn from our observation of their effects on drug-addicts. Psychopathology certainly has a significant impact of a detrimental sort on the outcome of treated subjects. A higher level of psychopathological impairment at treatment entrance renders stabilization more awkward to achieve and increases the likelihood that patients will drop out before any stable control of behavior is obtained. Though it is exacerbated by withdrawal, an addict's psychopathology is mostly due to acquired opioid dys-function resulting from chronic fast-acting (ie, heroin) opiate intoxication, and persists also in the absence of rebound phenomena. Conversely, it usually dwindles alongside the diminishing of craving and relapse events. Methadone-maintained subjects, who entered treatment with a high level of psychopathological impairment, require higher methadone dosages for stabilization to be achieved. More specifically, dosages tend to be higher for aggressive or irritable subjects, with violent or destructive behavior and intense feelings of rage. 67 Similarly, higher doses are useful in providing psychotic and paranoid patients with behavioral buffering, in enhancing the hypotrophic drive of dysthymic subjects, and in reducing unjustified somatic complaints. Interestingly, these same conditions, which may indicate a need for stronger opioid coverage, are correlated with a poor outcome in an antagonist-based maintenance program. In fact, psychotic, aggressive, and dysphoric subjects are unlikely to stay under naltrexone in a maintenance program (personal unpublished data). This incompatibility between opioid antagonism and psychopathology was discovered in a subgroup of addicts who were selected as fit for naltrexone treatment because of not being susceptible to withdrawal after naloxone administration. It follows that the psychopathological effects of opioidergic drugs used in the treatment of opiate abuse/addiction do not overlap with tolerance and withdrawalrelated phenomena.
The Pisa-Sia Group has also verified the impact of methadone maintenance upon dual diagnosis, by comparing the treatment outcomes of mentally ill addicts and uncomplicated peers. Dual diagnosis addicts need higher stabilization dosages and take longer to achieve stabilization, but they do not have a poorer outcome. 50 In fact, it seems that, as long as adequate dosages are used and enough time is spent under treatment, mentally ill addicts change their addictive attitude toward therapeutic goals. In fact, the 8-year retention rate of dual diagnosis addicts is even higher than that of their uncomplicated counterparts, showing a trend to stay in a maintenance program, which is just the opposite of addicts' preference for brief, unstructured, drug-tapering regimes. The length of time to be spent under treatment before achieving stabilization does not depend on the dosage level that is eventually reached, but reflects the need to gradually counter the pathophysiology of a dual mental illness instead of a single one. 60 Regarding bipolar I patients treated on Methadone Maintenance (MM), there are anecdotal observations that methadone helps as a mood stabilizer 68 and antypsychotic agent. 69 We observed that early retention is problematic. Bipolar I MM-treated patients need significantly higher methadone doses during stabilization than those required by addicts with no diagnosis of additional DSM-IV axis I mental disorders. If they survive early attrition, they tend to stay in treatment like heroin addicts without psychiatric comorbidity, but, among heroin addicts with psychiatric co-morbidity, they show a lower rate of retention in treatment, while the risk of their leaving the treatment remains high. 33 
CONCLUSIONS
On the basis of data gathered from the literature and our personal observations, it can be hypothesized that bipolarity is a risk factor for addictive behaviors. This is true for full-blown bipolar I disorder, 36 and even more so for its sub-bipolar expressions at a temperamental level. 1 The bipolarity of addicted individuals is often missed on cursory examination, because bipolar temperaments are not examined in practice. Instead, it is primarily the tip of the bipolar iceberg, bipolar I, that is recognized as relevant to addictions. Nonetheless, affective temperamental profiles do represent risk dispositions for substance abuse in healthy populations. 60 In clinical populations, bipolar I and II disorders represent the most frequent conditions of dual diagnosis among heroin addicts and cannabis-using chronic psychotic patients. Our work has shown that the distinction between heroin addicts and healthy controls is feasible along dimensions of temperamental bipolarity. Moreover, the suggestion can be made that cyclothymic bipolarity, borderline impulsivity, antisocial conduct, and substance abuse may, hypothetically, all take root in the same familial-genetic substrate. 19, 56 Heroin addicts constitute a unique clinical model for studying and describing the effects of chronic opioid damage and dysfunction, thus linking the clinical terrain to basic neurobiology. In fact, heroin addicts themselves, due to the prominent and distinctive psychopathological features they display (craving and relapse-proneness), fully fit the concept of mentally ill subjects. In any case, the more longstanding pharmacological knowledge acquired about the psychoactive properties of opioidergic drugs turns out to match the later body of information we have gathered from our experience with dual diagnosis heroin addicts. The mind-altering properties of rapid-acting and the counteracting therapeutic potential of slow-acting opiates are therefore crucial both in simple and in complex clinical pictures of addiction. Opioidergic drugs, such as methadone, should be perceived as psychoactive agents, with an ascertained usefulness in the treatment of addictive behavior, an enhanced therapeutic potential in combined clinical pictures featuring addiction together with other mental disorders, and as a possible resource for the treatment of non-addicted psychiatric patients.
